Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Santhera Pharmaceuticals
Santhera Pharmaceuticals
FDA Approves Novel Corticosteroid Treatment Option for DMD Patients
BioSpace
Fri, 10/27/23 - 11:47 am
Santhera Pharmaceuticals
Catalyst Pharmaceuticals
Agamree
FDA
DMD
Duchenne Muscular Dystrophy
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Wed, 02/22/23 - 10:00 am
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
Pharmaceutical Business Review
Tue, 01/10/23 - 10:42 am
Santhera Pharmaceuticals
ReveraGen
vamorolone
Duchenne Muscular Dystrophy
FDA
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Endpoints
Tue, 06/1/21 - 11:43 am
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
vamorolone
clinical trials
Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application
Fierce Biotech
Tue, 10/6/20 - 10:40 am
Santhera Pharmaceuticals
clinical trials
Duchenne Muscular Dystrophy
idebenone
